The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.

Autor: Zou J; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA., Jones RJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA., Wang H; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA., Kuiatse I; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA., Shirazi F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA., Manasanch EE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA., Lee HC; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA., Sullivan R; BioTheryX Inc., San Diego, CA, USA., Fung L; BioTheryX Inc., San Diego, CA, USA., Richard N; BioTheryX Inc., San Diego, CA, USA., Erdman P; BioTheryX Inc., San Diego, CA, USA., Torres E; BioTheryX Inc., San Diego, CA, USA., Hecht D; School of Mathematics, Science & Engineering, Southwestern College, Chula Vista, CA, USA., Lam I; BioTheryX Inc., San Diego, CA, USA., McElwee B; BioTheryX Inc., San Diego, CA, USA., Chourasia AH; BioTheryX Inc., San Diego, CA, USA., Chan KWH; BioTheryX Inc., San Diego, CA, USA., Mercurio F; BioTheryX Inc., San Diego, CA, USA., Stirling DI; BioTheryX Inc., San Diego, CA, USA., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA. rorlowski@mdanderson.org.; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rorlowski@mdanderson.org.

Publikováno v: Journal of molecular medicine (Berlin, Germany) [J Mol Med (Berl)] 2020 Aug; Vol. 98 (8), pp. 1161-1173. Date of Electronic Publication: 2020 Jul 06.

Reduced CC Chemokine Receptor 4 Expression in Tumor Cells after Lenalidomide Treatment for Adult T-Cell Leukemia/Lymphoma: A Case Report.

Autor: Shimizu, Masatomo¹ (AUTHOR), Yokote, Taiji¹ (AUTHOR), Hatooka, Jun¹ (AUTHOR), Kinoshita, Yuuki¹ (AUTHOR), Imagawa, Akihisa¹ (AUTHOR), Yasuda, Emi² (AUTHOR)

Publikováno v: Case Reports in Oncology. 2024, Vol. 17 Issue 1, p602-607. 6p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.